14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:CEMP
Delisted

Cempra Fund Predictions

$2.33
+0 (+0%)
At Close: Jan 16, 2018
Currently predicting for Thu, 9 May 2024

CEMP Predictions History

7 years ago
JS predicted that CEMP for 2017-05-03 is going $3.93 (2.08%)

7 years ago
JuanC Villegas predicted that CEMP for 2017-05-03 is going $3.85 (-2.53%)

7 years ago
E.Nessim.Roman.4816 predicted that CEMP for 2017-05-03 is going $4.40 (11.39%)

Rank:

7 years ago
SaladParty predicted that CEMP for 2017-05-03 is going $4.56 (15.44%)

Rank:

7 years ago
PIF predicted that CEMP for 2017-03-08 is going $3.68 (5.14%)

Rank:

7 years ago
PIFF predicted that CEMP for 2017-02-28 is going $4.30 (2.38%)

Rank:

7 years ago
JS predicted that CEMP for 2017-02-27 is going $4.71 (12.14%)

7 years ago
JS predicted that CEMP for 2017-01-09 is going $4.23 (12.80%)

7 years ago
Saadi.Malik.2153 predicted that CEMP for 2017-01-09 is going $3.91 (4.27%)

Rank:

7 years ago
JS predicted that CEMP for 2017-01-06 is going $3.28 (0.92%)

Click to get the best stock tips daily for free!

About Cempra

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates include solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia, as well as for uncomplicated bacterial urethritis; and Taksta, an antibiotic that has completed Phase II clinic... CEMP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT